The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) announced that the first patient has been enrolled in CIREL (CIRSE registry for LifePearl microspheres), a Europe-wide observational study that will gather data on transarterial chemoembolization (TACE) using LifePearl (Terumo) microspheres loaded with irinotecan in patients with colorectal cancer and liver metastases.
The pan-European observational study CIREL will enrol up to 500 patients with colorectal cancer and liver metastases receiving TACE using LifePearl microspheres loaded with irinotecan as part of their standard treatment. The study aims to observe and categorise the real-life use of the device in the context of patients’ cancer treatment and will also collect extensive data on the safety, toxicity, efficacy, and quality of life.
Maria José Sousa and Belarmino Gonçalves, interventional radiologists at Instituto Português de Oncologia do Porto, Portugal, are among the first to join CIREL. They pinpointed why they think participation in the registry is important: “Through collaborative effort, we can optimise treatment and standardise procedures to majorly benefit our patients. Positive study outcomes, furthermore, could lead to changes in evidence-based guidelines on locoregional treatments for metastatic colorectal cancer.”
For further information on the CIREL study, please contact: Robert Bauer on firstname.lastname@example.org, or visit www.cirse.org/cirel